Researchers have discovered that the PTPN22-PSTPIP1 signaling axis acts as a critical brake on actin remodeling during T-cell synapse formation, preventing the immune system from becoming hypersensitive. This finding provides biotech professionals with a mechanistic understanding of how genetic variants contribute to autoimmune diseases like lupus and rheumatoid arthritis. Insights into this cytoskeletal regulatory axis could inform the development of more precise cancer immunotherapies by allowing for better modulation of T-cell activation.
Read the full article at Genetic Engineering News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.





